Humanized anti-alpha v beta 5 antibodies and uses thereof
US-2017362324-A1 · Dec 21, 2017 · US
Methods and compositions for treating and preventing disease associated with αvβ5 integrin
US10087252B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10087252-B2 |
| Application number | US-201013386323-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2010 |
| Priority date | Jul 24, 2009 |
| Publication date | Oct 2, 2018 |
| Grant date | Oct 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. In particular, antibodies specific for αvβ5 integrin are useful for preventing, treating, and reversing sepsis.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating severe sepsis in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody specific for αvβ5 integrin, wherein said antibody specifically inhibits ligand binding to αvβ5 integrin and does not significantly bind to at least one of αvβ3, β3, αvβ6, β6, αvβ8 and β8 and wherein the antibody comprises the complementarity determining regions of the ALULA antibody produced by the hybridoma of ATCC Deposit No. PTA-5817. 2. The method of claim 1 , wherein the antibody does not significantly bind to any of αvβ3, β3, αvβ6, β6, αvβ8 or β8. 3. The method of claim 1 , wherein the antibody is a chimeric or a humanized antibody. 4. The method of claim 1 , wherein the ligand is selected from the group consisting of vitronectin, fibronectin, osteopontin, tenascin c, and adenovirus penton base. 5. The method of claim 1 , wherein the antibody is a humanized or chimeric ALULA. 6. The method of claim 1 , wherein the administration is intraperitoneal or intravenous. 7. A method of treating septic shock in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody specific for αvβ5 integrin, wherein said antibody specifically inhibits ligand binding to αvβ5 integrin and does not significantly bind to at least one of αvβ3, β3, αvβ6, β6, αvβ8 and β8 and wherein the antibody comprises the complementarity determining regions of the ALULA antibody produced by the hybridoma of ATCC Deposit No. PTA-5817. 8. The method of claim 7 , wherein the antibody does not significantly bind to any of αvβ3, β3, αvβ6, β6, αvβ8 or β8. 9. The method of claim 7 , wherein the antibody is a chimeric or a humanized antibody. 10. The method of claim 7 , wherein the ligand is selected from the group consisting of vitronectin, fibronectin, osteopontin, tenascin c, and adenovirus penton base. 11. The method of claim 7 , wherein the antibody is a humanized or chimeric ALULA. 12. The method of claim 7 , wherein the administration is intraperitoneal or intravenous.
Assignees
Inventors
Classifications
Drugs for disorders of the blood or the extracellular fluid · CPC title
Drugs for immunological or allergic disorders · CPC title
Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10087252B2 cover?
- The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. In particular, antibodies specific for αvβ5 integrin are useful for preventing, treating, and reversing sepsis.
- Who is the assignee on this patent?
- Sheppard Dean, Su George, Atakilit Amha, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2839. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).